BRCA1 and breast cancer: However, the knowledge of recurrent mutation in a particular ethnic group could still expedite the diagnosis and treatment among BC patients and related family members (Karami and Mehdipour, 2013), e.g., the three founders BRCA1/2 congenital mutations account for up to 99% of pathogenic variants amongst the Ashkenazi-Jewish community (Dillenburg et al., 2012).